• LAST PRICE
    0.9520
  • TODAY'S CHANGE (%)
    Trending Up0.0049 (0.5174%)
  • Bid / Lots
    0.9456/ 5
  • Ask / Lots
    0.9520/ 1
  • Open / Previous Close
    0.9500 / 0.9471
  • Day Range
    Low 0.9401
    High 0.9782
  • 52 Week Range
    Low 0.8354
    High 1.9300
  • Volume
    139,585
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.9471
TimeVolumePGEN
09:32 ET215850.97
09:34 ET37090.97
09:36 ET36780.9782
09:38 ET6000.9739
09:39 ET62580.9778
09:41 ET63000.9776
09:43 ET71190.9776
09:45 ET61550.9712
09:48 ET176240.96
09:50 ET7000.95795
09:54 ET8220.9621
09:57 ET12690.965
09:59 ET26000.9663
10:01 ET57440.9624
10:03 ET2000.9624
10:06 ET49670.9624
10:08 ET28650.9624
10:10 ET24310.9559
10:12 ET9800.9527
10:14 ET12420.9536
10:15 ET11920.9506
10:17 ET186640.9405
10:19 ET4000.94305
10:21 ET6000.9429
10:24 ET11000.943
10:26 ET20240.9447
10:28 ET10720.9447
10:30 ET9620.9415
10:32 ET33090.9423
10:33 ET7000.9443
10:35 ET14240.952
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPGEN
Precigen Inc
270.4M
-1.8x
---
United StatesSCPH
scPharmaceuticals Inc
228.1M
-2.8x
---
United StatesTELO
Telomir Pharmaceuticals Inc
190.1M
-8.8x
---
United StatesASPI
ASP Isotopes Inc
185.4M
-4.4x
---
United StatesHCIL
Hongchang International Co Ltd
140.1M
-450.0x
---
United StatesGBLP
Global Pharmatech Inc
138.3M
-3.6x
---
As of 2024-10-01

Company Information

Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Contact Information

Headquarters
20374 SENECA MEADOWS PARKWAYGERMANTOWN, MD, United States 20876
Phone
301-556-9900
Fax
---

Executives

Executive Chairman of the Board
Randal Kirk
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
Helen Sabzevari
Chief Financial Officer
Harry Thomasian
Chief Operating Officer
Rutul Shah
Senior Vice President - Intellectual Property Affairs
Jeffrey Perez

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$270.4M
Revenue (TTM)
$4.4M
Shares Outstanding
285.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.66
EPS
$-0.54
Book Value
$0.48
P/E Ratio
-1.8x
Price/Sales (TTM)
61.6
Price/Cash Flow (TTM)
---
Operating Margin
-3,199.20%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.